Technical Analysis for STTK - Shattuck Labs, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Multiple of Ten Bearish | Other | 0.00% | |
20 DMA Support | Bullish | 4.32% | |
Multiple of Ten Bearish | Other | 3.34% | |
Upper Bollinger Band Touch | Strength | 3.34% | |
New 52 Week Closing High | Bullish | -2.27% | |
Pocket Pivot | Bullish Swing Setup | -2.27% | |
Multiple of Ten Bullish | Other | -2.27% | |
Above Upper BB | Strength | -2.27% | |
Upper Bollinger Band Touch | Strength | -2.27% | |
Crossed Above 20 DMA | Bullish | -1.20% |
Alert | Time |
---|---|
Rose Above Upper Bollinger Band | about 11 hours ago |
60 Minute Opening Range Breakout | about 11 hours ago |
Up 5% | about 11 hours ago |
Upper Bollinger Band Resistance | about 11 hours ago |
Rose Above Previous Day's High | about 12 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Solid Tumors Autoimmune Disease Treatment Of Cancer Lymphoma Clinical Research Clinical Trial Ovarian Cancer Advanced Solid Tumors Clinical Pharmacology Treatment Of Ovarian Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Solid Tumors Autoimmune Disease Treatment Of Cancer Lymphoma Clinical Research Clinical Trial Ovarian Cancer Advanced Solid Tumors Clinical Pharmacology Treatment Of Ovarian Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.11 |
52 Week Low | 1.3301 |
Average Volume | 342,865 |
200-Day Moving Average | 5.14 |
50-Day Moving Average | 9.19 |
20-Day Moving Average | 9.29 |
10-Day Moving Average | 9.54 |
Average True Range | 0.65 |
RSI (14) | 56.52 |
ADX | 29.87 |
+DI | 29.28 |
-DI | 16.22 |
Chandelier Exit (Long, 3 ATRs) | 8.36 |
Chandelier Exit (Short, 3 ATRs) | 10.50 |
Upper Bollinger Bands | 10.13 |
Lower Bollinger Band | 8.46 |
Percent B (%b) | 0.86 |
BandWidth | 18.02 |
MACD Line | 0.17 |
MACD Signal Line | 0.12 |
MACD Histogram | 0.0433 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 10.90 | ||||
Resistance 3 (R3) | 10.85 | 10.47 | 10.74 | ||
Resistance 2 (R2) | 10.47 | 10.21 | 10.49 | 10.68 | |
Resistance 1 (R1) | 10.18 | 10.05 | 10.32 | 10.23 | 10.62 |
Pivot Point | 9.80 | 9.80 | 9.87 | 9.82 | 9.80 |
Support 1 (S1) | 9.51 | 9.54 | 9.66 | 9.57 | 9.18 |
Support 2 (S2) | 9.13 | 9.38 | 9.15 | 9.12 | |
Support 3 (S3) | 8.84 | 9.13 | 9.06 | ||
Support 4 (S4) | 8.90 |